Atlas Trials

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Clinical trial NCT05819866 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05819866
Sponsor
Minoryx Therapeutics, S.L.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cerebral Adrenoleukodystrophy (cALD)
Start date
2023-07-12
Primary completion
2027-05-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.